HCM
BBIO icon

Harvey Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Harvey Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
138,835
+81,550
+142% +$5.71M 2.13% 10
2026
Q1 		$4.25M Buy
57,285
+14,555
+34% +$1.05M 0.97% 32
2025
Q4 		$3.27M Sell
42,730
-100
-0.2% -$6.56K 0.7% 39
2025
Q3 		$2.22M Sell
42,830
-8,655
-17% -$422K 0.47% 45
2025
Q2 		$2.2M Buy
51,485
+34,485
+203% +$1.25M 0.52% 44
2025
Q1 		$588K Buy
17,000
+4,100
+32% +$138K 0.15% 61
2024
Q4 		$354K Buy
+12,900
New +$333K 0.08% 72

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Harvey Capital Management's BBIO Position: Q2 2026 in Review

Harvey Capital Management increased its BridgeBio Pharma (BBIO) stake by 142% in Q2 2026, buying an estimated $5.71M and bringing the position to 138,835 shares worth $10.3M. The position accounts for 2.13% of the portfolio, ranked #10.

Harvey Capital Management first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Harvey Capital Management held 138,835 shares of BridgeBio Pharma worth $10.3M as of Q2 2026.
  • Harvey Capital Management bought 81,550 BridgeBio Pharma shares in Q2 2026, an estimated $5.71M.
  • BridgeBio Pharma made up 2.13% of Harvey Capital Management's portfolio in Q2 2026, its #10 holding.
  • Harvey Capital Management first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Harvey Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.